Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

The rate of any cancer-positive biopsy following focal therapy was 44.6% (95% CI: 38.7–50.6%). The treatment failure rate—including radical treatment, whole-gland ablation, hormonal therapy, or ...